Notícias e Atividades da GT Medical Technologies

Fusão, aquisição e financiamento envolvendo GT Medical Technologies.

• GT Medical Technologies acaba de anunciar uma arrecadação de fundos de 100 milhões de dólares. (publicado em 10 de junho de 2026).

Veja o organograma con seus 13 executivos principais

Biografias mais buscadas da GT Medical Technologies

• Per Langoe, Chief Executive Officer
• Michael Garcia, Chief Medical Officer and Head of Clinical Develop...
• Jeff Lewis, Chief Commercial Officer

Recentes movimentos de executivos em GT Medical Technologies

• Dakota Fog, Strategic Account Manager, deixou a Companhia  (Notícia publicada em 19 de novembro de 2025).

Criar um alerta
para seguir os movimentos de executivos da GT Medical Technologies.

GT Medical Technologies possui 1.250 concorrentes concorrentes Thermo Fisher Scientific (Estados Unidos), Cytiva (Estados Unidos) e Philips (Holanda).

Popular M&A news in Equipamentos Médicos

• Think Surgical acaba de anunciar uma arrecadação de fundos de 65 milhões de dólares. (publicado em 16 de julho de 2026).
• Pearl Health acaba de anunciar uma arrecadação de fundos de 110 milhões de dólares. (publicado em 12 de julho de 2026).
• EQT has announced the acquisition of Corza Medical  (publicado em 9 de julho de 2026).

Outros contatos sugeridos na indústria do Equipamentos Médicos

• Ivan Tornos - Chairman, President and Chief Executive Officer da Zimmer Biomet
• Kevin Lobo - President, Chief Executive Office & Chairman of the Board da Stryker
• Marc Casper - Chairman of the Board, President and Chief Executive Officer da Thermo Fisher Scientific

Saiba mais sobre a indústria do Equipamentos Médicos

Últimos comunicados de imprensa de GT Medical Technologies

• GT Medical Technologies Completes Oversubscribed $100 Million Series E Equity Financing to Advance Commercial Treatment for Patients with Operable Brain Tumors
• Implanted Tile-Based Radiation Outperforms Stereotactic Radiotherapy for Treatment of Brain Metastases - ASCOBack ButtonSearch IconFilter Icon
• ROADS Phase 3 Clinical Trial Data Presented at ASCO26 Show GammaTile® Provides Superior Tumor Control Leading to Patients Living Longer Without Recurrence Compared to Standard of Care in Newly Diagnosed Operable Brain Metastases
• GT Medical Technologies Welcomes New GammaTile® Center of Excellence Program Designation
• GT Medical Technologies Raises $37 Million in Series D to Advance the Expansion of GammaTile® in the U.S. for Patients with Operable Brain Tumors
• GT Medical Technologies Achieves Two Clinical Milestones with GammaTile® to Help Treat Brain Tumors
• GT Medical Technologies, Inc. Secures $35 Million Venture Loan Facility from Horizon Technology Finance
• GT Medical Technologies Welcomes Two New C-Suite Members
• GT Medical Technologies, Inc. Appoints Two Industry Medical Device Veterans to Key Leadership Positions
• Albany Med participating in metastatic brain tumor study
• View more press releases Close

Redes sociais sobre GT Medical Technologies

• GT Medical Technologies na Wikipedia, Google News e Yahoo Finance
• GT Medical Technologies na LinkedIn, X (Twitter) e YouTube